AR086818A1 - Forma cristalina b de la 2,2,2-trifluoro-n-[(1r,2s)-1-[1-(4-fluorofenil)indazol-5-il]oxi-1-(3-metoxifenil)propan-2-il]acetamida - Google Patents

Forma cristalina b de la 2,2,2-trifluoro-n-[(1r,2s)-1-[1-(4-fluorofenil)indazol-5-il]oxi-1-(3-metoxifenil)propan-2-il]acetamida

Info

Publication number
AR086818A1
AR086818A1 ARP120102359A ARP120102359A AR086818A1 AR 086818 A1 AR086818 A1 AR 086818A1 AR P120102359 A ARP120102359 A AR P120102359A AR P120102359 A ARP120102359 A AR P120102359A AR 086818 A1 AR086818 A1 AR 086818A1
Authority
AR
Argentina
Prior art keywords
indazol
propan
trifluoro
acetamide
crystalline
Prior art date
Application number
ARP120102359A
Other languages
English (en)
Spanish (es)
Inventor
Ingemo Andersson Helena
Yvonne Conway Kelly
John Quayle Michael
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR086818A1 publication Critical patent/AR086818A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP120102359A 2011-06-29 2012-06-29 Forma cristalina b de la 2,2,2-trifluoro-n-[(1r,2s)-1-[1-(4-fluorofenil)indazol-5-il]oxi-1-(3-metoxifenil)propan-2-il]acetamida AR086818A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161502656P 2011-06-29 2011-06-29

Publications (1)

Publication Number Publication Date
AR086818A1 true AR086818A1 (es) 2014-01-22

Family

ID=46420454

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102359A AR086818A1 (es) 2011-06-29 2012-06-29 Forma cristalina b de la 2,2,2-trifluoro-n-[(1r,2s)-1-[1-(4-fluorofenil)indazol-5-il]oxi-1-(3-metoxifenil)propan-2-il]acetamida

Country Status (16)

Country Link
EP (1) EP2726464A1 (zh)
JP (1) JP2014527955A (zh)
KR (1) KR20140036230A (zh)
CN (1) CN103814015A (zh)
AR (1) AR086818A1 (zh)
AU (1) AU2012277514A1 (zh)
BR (1) BR112013031759A2 (zh)
CA (1) CA2839398A1 (zh)
IN (1) IN2014MN00023A (zh)
MX (1) MX2013014566A (zh)
RU (1) RU2013153466A (zh)
SG (1) SG195309A1 (zh)
TW (1) TW201305115A (zh)
UY (1) UY34170A (zh)
WO (1) WO2013001294A1 (zh)
ZA (1) ZA201309480B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017161518A1 (en) 2016-03-23 2017-09-28 Astrazeneca Ab New physical form
CN108314670B (zh) * 2018-02-06 2020-04-07 江苏八巨药业有限公司 一种(s)-2-氯-1-(6-氟-1-苯并二氢吡喃-2-基)-乙醇的制备方法
EP4253396A1 (en) * 2020-11-27 2023-10-04 Mirailab Bioscience Inc. High-purity beta-nicotinamide mononucleotide (nmn) and method for producing same
KR102571432B1 (ko) * 2023-02-08 2023-08-29 주식회사 에스씨엘테라퓨틱스 인다졸릴에스테르 및 아미드 유도체를 포함하는 암 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
SE9101090D0 (sv) 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
GB0315509D0 (en) 2003-07-02 2003-08-06 Meridica Ltd Dispensing device
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
WO2008079073A1 (en) 2006-12-22 2008-07-03 Astrazeneca Ab Indazolyl sulphonamide derivatives for the treatment of glucocorticoid receptor mediated disorders
IN2013MN00222A (zh) 2010-07-21 2015-05-29 Astrazeneca Ab
AU2011281318B2 (en) 2010-07-21 2013-09-19 Astrazeneca Ab Inhaler

Also Published As

Publication number Publication date
EP2726464A1 (en) 2014-05-07
BR112013031759A2 (pt) 2016-12-13
AU2012277514A1 (en) 2014-01-09
MX2013014566A (es) 2014-09-25
SG195309A1 (en) 2013-12-30
CN103814015A (zh) 2014-05-21
JP2014527955A (ja) 2014-10-23
RU2013153466A (ru) 2015-08-10
CA2839398A1 (en) 2013-01-03
TW201305115A (zh) 2013-02-01
IN2014MN00023A (zh) 2015-06-12
KR20140036230A (ko) 2014-03-25
WO2013001294A1 (en) 2013-01-03
UY34170A (es) 2013-01-31
ZA201309480B (en) 2015-10-28

Similar Documents

Publication Publication Date Title
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
NI201400070A (es) Compuestos de benzaldehído sustituidos y métodos para su uso en incrementar la oxigenación del tejido.
CL2013003227A1 (es) “compuestos derivados de indazol sustituidos, moduladores de la actividad de proteínas quinasas; proceso de obtención de ellos; método in vitro para inhibir proteínas quinasas; composición y combinación farmacéutica que los comprende; y su uso en el tratamiento del cáncer" pct
CL2016001120A1 (es) Compuestos derivados de pirrolo1,2-f1,2,4triazina ,composición farmacéutica que los comprende y su uso en el tratamiento de una infección por virus sincicial compuestos intermediarios. pct
NI201500142A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos.
AR084691A1 (es) Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel
CL2009001066A1 (es) Compuestos derivados del acido ciclopentano carboxilico sustituido; inhibidores del receptor lpa edg2; composicion farmaceutica; procedimiento de preparacion; y uso en el tratamiento de enfermedades cardiovasculares, inflamatorias, metabolicas, renales, pulmonares, oncologicas, inmunologicas y alergias, entre otras.
ECSP13012770A (es) Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina
DOP2014000133A (es) Triazolopiridinas sustituidas
ECSP10010489A (es) Nuevas formulaciones, comprimidos que comprenden tales formulaciones, su uso y procedimiento para su preparación
UY33370A (es) Composiciones farmacéuticas comprendiendo un fármaco inhibidor de la DPP4 y de la pioglitazona, procedimientos de preparación y utilización
CL2012002737A1 (es) Anticuerpo anti-cd40 humanizado; polinucleótido que lo codifica; composición farmacéutica que comprende dicho anticuerpo; y su uso para bloquear una respuesta inmunitaria mediada por cd40 humana.
UY32427A (es) Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
CR20130033A (es) Formulaciones de rifaximina y usos de las mismas
ECSP13012368A (es) Composiciones farmacéuticas de co-cristales de tramadol y coxibs
CR20160222U (es) Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
ECSP13013011A (es) Triazolopiridinas
CL2009001484A1 (es) Sal glicinato de metformina; composición farmacéutica que comprende la sal; y su uso para tratar la hiperglicemia.
DOP2016000253A (es) Nuevos compuestos
CR20140175A (es) Compuestos y métodos para mejorar las respuestas inmunitarias innatas
UY34008A (es) ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?.
UY32052A (es) 5-aminopirazoles sustituidos y uso de los mismos
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
CL2012000097A1 (es) Compuestos derivados de 3-fenoximetilpirrolidina, inhibidores de la recaptacion de serotonina-norepinefrina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos del dolor, depresion, entre otros.

Legal Events

Date Code Title Description
FB Suspension of granting procedure